Description
In June, the U.S. Food and Drug Administration (FDA) approved the use of Elevidys, the first gene therapy for Duchenne muscular dystrophy.
The FDA based its ruling on research that showed the treatment slowed the progression of the disease, but its use was only approved for patients who are 4 and 5 years old.
"It's kind of funny because so many people have been focusing on our good news, but there's bad news too," said mother Heather Hay, who has two sons with Duchenne muscular dystrophy.
Kellen is 5, but big brother Liam is 8.
Read the full story: https://www.king5.com/article/news/local/duchenne-muscular-dystrophy-fda-gene-therapy-olympia-family-eligibility/281-27a01e21-c31d-4b3b-813e-ad884ec2e0f2